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Abstract 
Aims: High-density lipoprotein (HDL) cholesterol is a strong predictor of cardiovascular 
mortality. This work aimed to investigate, whether the presence of coronary artery disease 
(CAD) impacts on its predictive value. 
Methods and Results: We studied 3,141 participants (2,191 males, 950 females) of the 
LUdwigshafen RIsk and Cardiovascular health study. They had a mean±standard deviation 
age of 62.6±10.6 years, body mass index of 27.5±4.1 kg/m², and HDL cholesterol of 
38.9±10.8 mg/dl. The cohort consisted of 699 people without CAD, 1,515 patients with stable 
CAD, and 927 patients with unstable CAD. The participants were prospectively followed for 
cardiovascular mortality over a median (interquartile range) period of 9.9 (8.7-10.7) years. A 
total of 590 participants died from cardiovascular diseases. HDL cholesterol by tertiles was 
inversely related to cardiovascular mortality in the entire cohort (p=0.009). There was 
significant interaction between HDL cholesterol and CAD in predicting the outcome 
(p=0.007). In stratified analyses, HDL cholesterol was strongly associated with cardiovascular 
mortality in people without CAD (3
rd
 vs. 1
st
 tertile: HR(95%CI)=0.37 (0.18-0.74), p=0.005), 
but not in patients with stable (3
rd
 vs. 1
st
 tertile: HR(95%CI)=0.81 (0.61-1.09), p=0.159) and 
unstable (3
rd
 vs. 1
st
 tertile: HR(95%CI)=0.91 (0.59-1.41), p=0.675) CAD. These results were 
replicated by analyses in 3,413 participants of the AtheroGene cohort and 5,738 participants 
of the ESTHER cohort, and by a meta-analysis comprising all three cohorts.  
Conclusion: The inverse relationship of HDL cholesterol with cardiovascular mortality is 
weakened in patients with CAD. The usefulness of considering HDL cholesterol for 
cardiovascular risk stratification seems limited in such patients. 
 
Key words: High density lipoprotein cholesterol, atherosclerosis, cardiovascular mortality
 3 
Introduction 1 
Epidemiologic data have provided broad evidence that low concentrations of high-density 2 
lipoprotein (HDL) cholesterol indicate increased cardiovascular risk (1-4). Although less 3 
consistently (5), this relationship is even apparent in patients treated with statins (6). 4 
Therefore, raising HDL cholesterol has become a therapeutic target in coronary artery disease 5 
(CAD) (7). 6 
Inhibition of cholesterol-ester transfer protein (CETP) is associated with a substantial increase 7 
of HDL cholesterol (8-12). Nevertheless, the use of torcetrapib did not improve but rather 8 
worsened prognosis in the ILLUMINATE trial (11). Treatment with dalcetrapib did not 9 
reduce the risk of cardiovascular events in the recently published dal-OUTCOMES trial either 10 
(12). These disappointing results may in part be attributed to off-target effects of cholesterol 11 
ester transfer protein (CETP) inhibitors, most importantly an increase in systolic blood 12 
pressure and pro-inflammatory activity (11, 12).  An alternative explanation would be that 13 
raising HDL cholesterol is less beneficial in certain subgroups, for example in patients with 14 
CAD. Notably, ILLUMINATE included patients at high cardiovascular risk and all 15 
participants of the dal-OUTCOMES trial had suffered a recent acute coronary syndrome (11. 16 
12). 17 
Therefore, the aim of the present study was to investigate, whether CAD at baseline affects 18 
the prognostic value of HDL cholesterol for cardiovascular mortality. The exploratory 19 
analyses were performed in the “LUdwigshafen RIsk and Cardiovascular health” (LURIC) 20 
cohort (13, 14). Replication of the findings obtained from LURIC was sought in the 21 
AtheroGene (15, 16) and the ESTHER (17, 18) cohorts. Considering that their clinical 22 
presentation, treatment, and prognosis differ markedly, stable and unstable CAD were 23 
analyzed separately. 24 
 4 
Methods 1 
Study design, participants and clinical characterization 2 
LURIC 3 
A total of 3,316 patients, who were referred for coronary angiography to the Ludwigshafen 4 
Heart Center in South-West Germany, were recruited between July 1997 and January 2000 5 
(13). Inclusion criteria were: German ancestry, clinical stability except for acute coronary 6 
syndromes, and the availability of a coronary angiogram. The indications for angiography in 7 
individuals in clinically stable condition were chest pain and/or noninvasive test results 8 
consistent with myocardial ischemia. Individuals suffering from any acute illness other than 9 
acute coronary syndromes, chronic non-cardiac diseases, or malignancy within the five past 10 
years, and those unable to understand the purpose of the study were excluded. Subjects with 11 
missing information on the clinical presentation of CAD, missing laboratory measurements or 12 
missing information on the cause of death were additionally ruled out resulting in a subgroup 13 
of 3,141 participants for the present analyses. CAD was diagnosed if coronary angiography 14 
revealed stenosis of one or more vessels ≥20%.  Unstable angina was diagnosed according to 15 
Braunwald (13). Acute myocardial infarction was defined as a myocardial infarction that had 16 
occurred within the four weeks prior to enrolment into LURIC. A definite ST-elevation 17 
myocardial infarction was diagnosed if typical electrocardiogram changes were present along 18 
with prolonged chest pain, refractory to sublingual nitrates and/or enzyme or troponin T 19 
elevations (>0.1 g/L). Non ST-elevation myocardial infarction was diagnosed, if symptoms 20 
and troponin T criteria, but not the ECG criteria for ST-elevation myocardial infarction were 21 
met (13). The functional capacity of patients with cardiac disease, especially heart failure, was 22 
estimated according to a classification developed by the New York Heart Association 23 
(NYHA) (13). Left ventricular function was estimated using echocardiography (13). 24 
 25 
 26 
 5 
AtheroGene  1 
A total of 3,800 patients, who underwent coronary angiography at the Department of 2 
Medicine II of the Johannes Gutenberg-University Mainz or the Bundeswehr-3 
Zentralkrankenhaus Koblenz, were recruited between June 1999 and March 2000 (15, 16). 4 
The exclusion
 
criteria were evidence of hemodynamically significant valvular
 
heart disease, 5 
surgery or trauma within the previous month,
 
known cardiomyopathy, known cancer, febrile 6 
conditions, or use
 
of oral anticoagulant therapy within the previous four weeks (15, 16). 7 
Subjects with missing information on the clinical presentation of CAD, missing laboratory 8 
measurements or missing information on the cause of death were additionally ruled out 9 
resulting in a subgroup 3,413 participants for the present analyses. CAD was diagnosed if the 10 
coronary angiogram showed at least one stenosis >30 % in a major coronary artery. Unstable 11 
angina was diagnosed according to Braunwald. Acute myocardial infarction was either ST-12 
segment elevation with significant elevation in at least two contiguous leads or non-ST 13 
elevation myocardial infarction based on clinic and positive in-house troponin concentrations 14 
(16). 15 
 16 
ESTHER 17 
A total of 9,949 subjects were recruited for the “Epidemiologische Studie zu Chancen der 18 
Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren 19 
Bevölkerung (German)“ by their general practitioners during a routine health check-up 20 
between 2000 and 2002 in the German federal state Saarland (17, 18). The distribution of 21 
socio-demographic baseline characteristics and common prevalent chronic diseases were 22 
similar to the distribution in the respective age categories in the German National Health 23 
Survey, which is a representative sample of the German population (17), a fact supporting the 24 
population-based character of the study. We excluded study participants due to unmeasured 25 
HDL cholesterol, due to an unknown cause of death, and due to self-reported history of CAD 26 
 6 
that was not physician-confirmed, leaving a subgroup of 5,738 participants for the present 1 
analysis. CAD was defined by physician-reported CAD (17, 18).  2 
 3 
Ethical approval and written informed consent 4 
All three studies were approved by the local ethics committees and performed in accordance 5 
with the declaration of Helsinki. All participants gave written informed consent (13-18).  6 
 7 
Follow-up 8 
In the LURIC cohort, there was a follow-up for cardiovascular mortality with a mean ± 9 
standard deviation duration of 8.9 ± 3.0 years (median and interquartile range: 9.9, 8.7-10.7). 10 
Information on the vital status was obtained from local person registries. Using death 11 
certificates two experienced clinicians independently classified the causes of death. They 12 
were masked to any other data of the study participants. In a few cases of a disagreement or 13 
uncertainty concerning the coding of a specific cause of death, classification was made by a 14 
principal investigator of the LURIC study (W. M.) (13). In the AtheroGene cohort, there was 15 
a follow-up for cardiovascular mortality with a mean ± standard deviation duration of 4.5 ± 16 
2.0 years (median and interquartile range: 4.4, 2.9-6.3). Information about the causes of death 17 
and clinical events was obtained from hospital and general-practitioner charts. In the 18 
ESTHER cohort, there was a follow-up for cardiovascular mortality with a mean ± standard 19 
deviation duration of 9.1 ± 1.6 years (median and interquartile range: 9.4, 8.9-9.9). Deaths 20 
were identified by inquiry at the residents’ registration offices. All deaths coded with ICD-10-21 
codes I00-I99 were considered to be cardiovascular deaths.  22 
 23 
 24 
 25 
 26 
 7 
Laboratory analyses 1 
All analyses were performed in fasting blood samples. In the LURIC and AtheroGene 2 
cohorts, the blood samples were collected before angiography (13-16). In the ESTHER 3 
cohort, the blood samples were taken during the health check-up (17, 18). 4 
In the LURIC cohort, the lipoproteins were separated using a combined ultracentrifugation-5 
precipitation method (ß quantification) (13). Cholesterol was measured with enzymatic 6 
reagents from WAKO (Neuss, Germany) on a WAKO 30 R or Olympus AU640 (Tokyo, 7 
Japan) analyzer (13). Triglycerides were quantified with an enzymatic colour assay on a 8 
Hitachi 717 analyzer (Roche, Mannheim, Germany) (13). Apoplipoproteins A1, A2, and B 9 
were measured by turbidimetry (Rolf-Greiner Biochemica, Flacht, Germany) (13). In the 10 
AtheroGene cohort, total cholesterol, triglycerides were measured enzymatically (Roche 11 
Diagnostics, Mannheim, Germany). HDL cholesterol was measured after masking 12 
apolipoprotein B immunologically (Rolf Greiner Biochemica, Flacht, Germany). LDL 13 
cholesterol was calculated by the Friedewald formula (15, 16). In the ESTHER cohort, total 14 
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were measured with 15 
standard methods (17, 18).  16 
 17 
Statistical analysis 18 
Tertiles of HDL cholesterol were formed in each cohort. The baseline characteristics are 19 
presented as counts and percentages of subjects in cases of categorical data and as means and 20 
standard deviations or medians with inter-quartile ranges in cases of continuous data for the 21 
tertiles of HDL cholesterol. The χ²-test and ANalysis Of VAriance were used to compare the 22 
distributions of the variables across the tertiles of HDL cholesterol. Triglycerides (Shapiro-23 
Wilk W test) were transformed logarithmically before being used in parametric statistical 24 
procedures. The Cox proportional hazards model was used to examine the association 25 
between HDL cholesterol and time to cardiovascular death. For exploratory purposes, the 26 
 8 
associations of the HDL cholesterol tertiles with cardiovascular mortality were first studied in 1 
the entire LURIC cohort. Two predefined models of adjustment were used (model 1: adjusted 2 
for sex, age, and CAD;  model 2: adjusted for sex, age, body mass index, systolic and 3 
diastolic blood pressure, diabetes mellitus, smoking, glomerular filtration rate, triglycerides, 4 
low density lipoprotein cholesterol, medication use (insulin, oral antidiabetic, ß-Blocker, ACE 5 
inhibitor, calcium antagonist, diuretic, acetyl salicylic acid, and statin), and CAD). Moreover, 6 
the interaction between the HDL cholesterol tertiles and CAD with regard to cardiovascular 7 
mortality was studied by including the interaction term as a covariate. In the next step, 8 
stratified analyses in people without CAD, in patients with stable CAD, and in patients with 9 
unstable CAD were conducted using the aforementioned models of adjustment. For 10 
replication, the associations of the HDL cholesterol tertiles with cardiovascular mortality were 11 
studied in the AtheroGene and ESTHER cohorts, which were stratified accordingly. All 12 
statistical tests were 2-sided and p values <0.05 were considered significant. The SPSS 19.0 13 
statistical package (SPSS Inc., Chicago, USA) was used in the LURIC and ESTHER cohorts. 14 
The R statistical software package (http://www.r-project.org) was used in the AtheroGene 15 
cohort. For meta-analyses of the results obtained from the LURIC, AtheroGene, and ESTHER 16 
cohorts, HRs were pooled by the inverse of the variance method in a fixed effects model with 17 
the software Comprehensive Meta-Analysis®.  18 
 19 
Role of the funding source 20 
The funding source was not involved in study design, in the collection, analysis, and 21 
interpretation of data, in the writing of the report, and in the decision to submit the paper for 22 
publication.  23 
 9 
Results 1 
LURIC 2 
Baseline characteristics 3 
The study participants (2,191 males, 950 females) had a mean ± standard deviation age of 4 
62.6 ± 10.6 years, body mass index of 27.5 ± 4.1 kg/m², and HDL cholesterol of 38.9 ± 10.8 5 
mg/dl. High HDL cholesterol was associated with female gender, lower body mass index and 6 
waist circumference, and lower proportion of subjects with diabetes mellitus (table 1). HDL 7 
cholesterol was positively related to total, low density lipoprotein, and very low density 8 
lipoprotein cholesterol and inversely related to triglycerides (table 1). Furthermore, HDL 9 
cholesterol was positively related to apolipoprotein A1, apolipoprotein A2, and inversely to 10 
apolipoprotein B (table 1). Prevalent stable and unstable CAD, cerebral vascular disease, and 11 
peripheral vascular disease were more frequent in people with low HDL cholesterol (table 1). 12 
Moreover, low HDL cholesterol went in parallel with impaired left ventricular function (table 13 
1). Use of insulin, oral antidiabetics, ß-blockers, ACE-inhibitors, diuretics, statins, and acetyl 14 
salicylic acid were more frequent in subjects with low HDL cholesterol (table 1). The 15 
baseline characteristics stratified for patients without CAD, patients with stable CAD, and 16 
those with unstable CAD are shown in supplementary table 1. There were no major 17 
differences in the mean HDL cholesterol concentrations among the corresponding HDL 18 
cholesterol tertiles of the subgroups without CAD, with stable CAD, and with unstable CAD 19 
(supplementary table 1).  20 
 21 
Prospective analyses 22 
A total of 925 deaths occurred during follow-up. Among these, 590 were due to 23 
cardiovascular diseases. In the entire cohort, the HDL cholesterol tertiles were inversely 24 
related to cardiovascular mortality (p=0.009) (table 2). However, further investigations 25 
disclosed significant interaction between the HDL cholesterol tertiles and CAD with regard to 26 
 10 
cardiovascular mortality in model 1 (p=0.146 and p=0.004 for 2
nd
 and 3
rd
 tertile versus 1
st
 1 
tertile, respectively) and in model 2 (p=0.178 and p=0.007 for 2
nd
 and 3
rd
 tertile versus 1
st
 2 
tertile, respectively). Subsequent analyses were therefore stratified by presence of CAD. By 3 
doing so, the tertiles of HDL cholesterol were strongly associated with cardiovascular 4 
mortality in participants without CAD (p=0.005), but not in participants with stable (p=0.162) 5 
or unstable (p=0.675) CAD (table 3). When we independently formed the HDL cholesterol 6 
tertiles within the subgroups resulting in similar numbers of participants for the three tertiles, 7 
the associations of the HDL-C tertiles with cardiovascular mortality still remained significant 8 
in participants without CAD, but not in participants with stable and unstable CAD (data not 9 
shown). 10 
 11 
AtheroGene 12 
Baseline characteristics 13 
The study participants (2,568 males, 845 females) had a mean ± standard deviation age of 14 
61.8 ± 10.0 years, body mass index of 27.5 ± 3.9 kg/m², and HDL cholesterol of 49.2 ± 14.6 15 
mg/dl. The baseline characteristics of the AtheroGene cohort stratified for patients without 16 
CAD, patients with stable CAD, and those with unstable CAD are shown in supplementary 17 
table 2.  18 
 19 
Prospective analyses 20 
A total of 381 deaths occurred during follow-up. Among these, 264 were due to 21 
cardiovascular diseases. Low HDL cholesterol was strongly associated with increased 22 
cardiovascular mortality in people without CAD (table 4). The association between HDL 23 
cholesterol and cardiovascular mortality was less pronounced in patients with stable CAD and 24 
turned non-significant after multivariate adjustment (table 4).  In patients with unstable CAD, 25 
 11 
there was no significant association between the tertiles of HDL cholesterol and 1 
cardiovascular mortality (table 4). 2 
 3 
ESTHER 4 
Baseline characteristics 5 
The study participants (2,606 males, 3,132 females) had a mean ± standard deviation age of 6 
62.0 ± 6.6 years, body mass index of 27.7 ± 4.3 kg/m², and HDL cholesterol of 53.5 ± 15.3 7 
mg/dl.  The baseline characteristics of the ESTHER cohort stratified for people without CAD 8 
and patients with stable CAD are shown in supplementary table 3.  9 
 10 
Prospective analyses 11 
A total of 586 deaths occurred during the follow-up. Among these, 196 deaths were due to 12 
cardiovascular diseases. HDL cholesterol was inversely related to cardiovascular mortality in 13 
people without CAD (table 4). This association reached statistical significance comparing the 14 
2
nd
 to the 1
st
 tertile of HDL cholesterol (table 4). In patients with stable CAD, there was no 15 
significant association between the tertiles of HDL cholesterol and cardiovascular mortality 16 
(table 4). 17 
 18 
Meta-analysis 19 
The meta-analysis comprised 12,292 participants of the LURIC, AtheroGene and ESTHER 20 
cohorts. In the subgroup of 5,791 people without CAD, the HDL cholesterol tertiles were 21 
significantly, inversely related to cardiovascular mortality (table 5). In contrast, the HDL 22 
cholesterol tertiles were not significantly related to cardiovascular mortality in the 4,304 23 
patients with stable CAD and the 2,197 patients with unstable CAD (table 5). 24 
 12 
Discussion 1 
The present data from a total of 12,292 participants of the LURIC, the AtheroGene, and the 2 
ESTHER cohorts show that CAD modulates the association of HDL cholesterol with 3 
cardiovascular mortality.  4 
HDL cholesterol tertiles were significantly, inversely related to cardiovascular mortality in the 5 
entire LURIC cohort. Inclusion of the interaction term between CAD and HDL cholesterol 6 
indicated variation in the predictive value of HDL cholesterol for cardiovascular mortality 7 
according to the presence of CAD. In stratified analyses, the association between the HDL 8 
cholesterol tertiles and cardiovascular mortality was strong in people without CAD whereas it 9 
was weak and non-significant after multivariate adjustment in patients with stable and 10 
unstable CAD. Very similar observations were made in the AtheroGene cohort. The 11 
aforementioned differences were less pronounced in the ESTHER cohort, possibly due to the 12 
lack of coronary angiograms and consequently a large proportion of undiagnosed, silent CAD. 13 
Finally, a meta-analysis comprising all three cohorts was performed and the results were in 14 
support of the LURIC findings. 15 
Previous studies have not specifically addressed an interaction of HDL with CAD, probably 16 
because very few studies have collected precise information on both, CAD at baseline and 17 
cardiovascular death. However, our results are in agreement with evidence from the dal-18 
OUTCOMES trial (12). In this cohort of 15,871 patients, who had suffered acute coronary 19 
syndromes, HDL cholesterol was not predictive of the primary end-point (12). Moreover, the 20 
present observations are confirmed by recent data on the cholesterol efflux capacity from 21 
macrophages to serum, which is positively related to HDL cholesterol (19, 20). In cross-22 
sectional analyses, low cholesterol efflux capacity was repeatedly associated with higher 23 
prevalence of CAD (19, 20). At the same time, the cholesterol efflux capacity was positively 24 
associated with the risk of future vascular complications in patients with CAD whereas no 25 
such paradox association was seen in an outpatient cohort (20).  26 
 13 
Two potential reasons, that may explain the interaction between the HDL cholesterol tertiles 1 
and CAD with regard to cardiovascular mortality, shall be highlighted: First, dysfunctional 2 
HDL may account for weaker associations of HDL cholesterol with cardiovascular mortality 3 
in CAD. HDL is considered to represent the major vehicle of reverse cholesterol transport 4 
(21-23). In addition, HDL may exert anti-inflammatory effects, prevent low-density 5 
lipoprotein oxidation, and play an important role in nitric oxide synthesis (21-23). Even anti-6 
thrombotic potency has been suggested (21-23). Nevertheless, there is growing knowledge 7 
that the vascular protective properties of HDL are impaired in certain diseases (24, 25). Most 8 
importantly, the anti-inflammatory and anti-oxidative effects of HDL were demonstrated to be 9 
reduced in CAD (26, 27). In the LURIC cohort, the apolipoprotein A1 and A2 composition of 10 
HDL did not explain the key finding (supplementary text). Future studies within the LURIC 11 
cohort will address other aspects of HDL functionality. Second, multimodal treatment of 12 
cardiovascular risk factors and co-morbidity may have blunted the relationships of HDL 13 
cholesterol with cardiovascular mortality in patients with CAD. However, exploratory 14 
analyses within the LURIC cohort did not support this possibility (supplementary text). 15 
It is a limitation of our study that HDL cholesterol was measured once at baseline only. 16 
Therefore, we were not able to adjust for possible moderate fluctuations of HDL cholesterol 17 
during the follow-up, for example due to the start of statin treatment or an increase of the 18 
statin dose (28). The major strength of this work is the detailed clinical and metabolic 19 
investigation of the LURIC participants including coronary angiography. Moreover, we want 20 
to emphasise the long duration of the follow-up with a large number of fatal cardiovascular 21 
events. In addition, our conclusions rely on replication in 3,413 participants of the 22 
AtheroGene cohort and 5,738 participants of the ESTHER cohort, and on a meta-analysis 23 
comprising all three cohorts.  24 
 14 
To sum up, the association of HDL cholesterol with cardiovascular mortality is weakened in 1 
the presence of CAD. The usefulness of measuring HDL cholesterol for cardiovascular risk 2 
stratification may be limited in secondary prevention.  3 
 15 
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Table 1 
 
Title: Baseline characteristics according to tertile of HDL cholesterol in the LURIC cohort 
 
     
 1
st
 tertile 2
nd
 tertile 3
rd
 tertile  
 ______________________________________  
Number 1048 1083 1010 P 
Male sex 868 (82.8) 776 (71.7) 547 (54.2) <0.001 
Age, years 61.8±11.1 62.6±10.2 63.6±10.4 0.001 
Body mass index, kg/m² 28.1±4.1 27.8±4.1 26.6±3.9 <0.001 
Waist circumference, cm † 101±11 100±11 96±12 <0.001 
Hypertension 767 (73.2) 798 (73.7) 732 (72.5) 0.822 
Systolic blood pressure, mmHg 139±24 142±23 143±23 0.001 
Diastolic blood pressure, mmHg 80±12 82±11 82±11 <0.001 
Diabetes mellitus 510 (48.7) 438 (40.4) 293 (29.0) <0.001 
Smoking    <0.001 
Never 285 (27.2) 383 (35.4) 468 (46.3)  
Former smoker 504 (48.1) 492 (45.4) 410 (40.6)  
Current smoker 259 (24.7) 208 (19.2) 132 (13.1)  
Lipids‡     
Total cholesterol, mg/dl 182±41 194±37 203±36 <0.001 
LDL cholesterol, mg/dl  106±35 120±33 124±33 <0.001 
HDL cholesterol, mg/dl  28±4 38±3 51±8 <0.001 
VLDL cholesterol, mg/dl 46±33 37±24 28±18 <0.001 
Triglycerides, mg/dl  173 (128-241) 149 (114-201) 122 (93-161) <0.001§ 
Apolipoprotein A1, mg/dl 108±15 128±13 155±19 <0.001 
Apolipoprotein A2, mg/dl 36±8 42±8 48±9 <0.001 
Apolipotrotein B, mg/dl 106±26 106±24 101±23 <0.001 
GFR, ml/min/1.73m² 80±20 83±19 81±18 0.022 
Coronary artery disease    <0.001 
No CAD 142 (13.5) 233 (21.5) 324 (32.1)  
Stable CAD 509 (48.6) 535 (49.4) 471 (46.6)  
Unstable CAD 397 (37.9) 315 (29.1) 215 (21.3)  
Presentation of unstable CAD    <0.001 
Unstable Angina 223 (21.3) 217 (20.0) 181 (17.9)  
NSTEMI 61 (5.8) 34 (3.1) 19 (1.9)  
STEMI 113 (10.8) 64 (5.9) 15 (1.5)  
NYHA functional class    0.339 
1 527 (50.3) 569 (52.5) 509 (50.4)  
2 302 (28.8) 319 (29.5) 314 (31.1)  
3 189 (18.0) 157 (14.5) 157 (15.5)  
4 30 (2.9) 38 (3.5) 30 (3.0)  
Left ventricular function (echo) ||    <0.001 
Normal 542  (53.1) 665 (62.9) 723 (72.7)  
Mildly impaired 163 (16.0) 155 (14.7) 116 (11.7)  
Moderately impaired 136 (13.3) 123 (11.6) 76  (7.6)  
Severely impaired 77 (7.5) 36 (3.4) 28 (2.8)  
Peripheral vascular disease 147 (14.0) 86 (7.9) 66 (6.5) <0.001 
Cerebrovascular disease 123 (11.7) 87 (8.0) 76 (7.5) 0.001 
Medication use     
Insulin 70 (6.7) 59 (5.4) 38 (3.8) 0.013 
Oral antidiabetic 125 (11.9) 84 (7.8) 46 (4.6) <0.001 
ß-Blocker 730 (69.7) 697 (64.4) 552 (54.7) <0.001 
ACE inhibitor 637 (60.8) 565 (52.2) 455 (45.0) <0.001 
Calcium antagonist 156 (14.9) 169 (15.6) 174 (17.2) 0.331 
Diuretic 366 (34.9) 286 (26.4) 244 (24.2) <0.001 
Statin 576 (54.9) 530 (48.9) 408 (40.4) <0.001 
 20 
Acetyl salicylic acid 790 (75.4) 773 (71.4) 672 (66.5) <0.001 
     
 
Legend: Values are means ± standard deviations or medians (25
th
-75
th
 percentiles) in cases of 
continuous variables and numbers (percentages) in case of categorical data; * for differences 
across the three groups calculated with chi-square test and ANalysis Of VAriance for 
categorical and continuous data, respectively; † numbers: 1035/1073/994; ‡ to convert values 
for total, LDL, HDL, and VLDL cholesterol to millimoles per liter, multiply by 0.02586; to 
convert values for triglycerides to millimoles per liter, multiply by 0.01129; § ANalysis Of 
VAriance of logarithmically transformed values; || numbers: 918/979/943 
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Table 2 
 
Title: Cardiovascular mortality according to tertile of HDL cholesterol in the LURIC cohort 
 
     
 N CD HR P 
     
Model 1 *     
1
st 
tertile 1048 248 (23.7) 1.0 reference  
2
nd
 tertile 1083 190 (17.5) 0.71 (0.59-0.86) <0.001 
3
rd
 tertile 1010 152 (15.0) 0.59(0.36-0.80) <0.001 
     
Model 2 †     
1
st 
tertile 1048 248 (23.7) 1.0 reference  
2
nd
 tertile 1083 190 (17.5) 0.82 (0.67-1.00) 0.052 
3
rd
 tertile 1010 152 (15.0) 0.74 (0.59-0.93) 0.009 
     
 
Legend: N number; CD number of cardiovascular deaths (percentage of tertile); HR hazard 
ratio (calculated with Cox proportional hazards model); * adjusted for sex, age, and CAD; † 
adjusted for sex, age, body mass index, systolic and diastolic blood pressure, diabetes, 
smoking, glomerular filtration rate, triglycerides, LDL cholesterol, medication use (insulin, 
oral antidiabetic, ß-Blocker, ACE inhibitor, calcium antagonist, diuretic, acetyl salicylic acid, 
and statin), and CAD 
22 
 
Table 3 
 
Title: Cardiovascular mortality according to tertile of HDL cholesterol stratified for CAD in the LURIC cohort 
 
             
 No CAD Stable CAD Unstable CAD 
 _____________________________ _____________________________ _____________________________ 
 N CD HR P N CD HR P N CD HR P 
             
Model 1 *             
1
st 
tertile 142 22 (15.5) 1.0 reference  509 138 (27.1) 1.0 reference  397 88 (22.2) 1.0 reference  
2
nd
 tertile 233 20 (8.6) 0.44 (0.24-0.81) 0.008 535 114 (21.3) 0.74 (0.58-0.95) 0.017 315 56 (17.8) 0.75 (0.53-1.04) 0.085 
3
rd
 tertile 324 19 (5.9) 0.27 (0.14-0.50) <0.001 471 94 (20.0) 0.67 (0.51-0.87) 0.003 215 39 (18.1) 0.65 (0.44-0.96) 0.030 
             
Model 2 †             
1
st 
tertile 142 22 (15.5) 1.0 reference  505 138 (27.1) 1.0 reference  397 88 (22.2) 1.0 reference  
2
nd
 tertile 233 20 (8.6) 0.54 (0.28-1.06) 0.074 535 114 (21.3) 0.83 (0.64-1.08) 0.162 315 56 (17.8) 0.88 (0.62-1.26) 0.485 
3
rd
 tertile 324 19 (5.9) 0.37 (0.18-0.74) 0.005 471 94 (20.0) 0.81 (0.61-1.09) 0.159 215 39 (18.1) 0.91 (0.59-1.41) 0.675 
             
 
Legend: N number; CD number of cardiovascular deaths (percentage of tertile); HR hazard ratio (calculated with Cox proportional hazards model); 
* adjusted for sex and age; † adjusted for sex, age, body mass index, systolic and diastolic blood pressure, diabetes, smoking, glomerular filtration 
rate, triglycerides, LDL cholesterol, and medication use (insulin, oral antidiabetic, ß-Blocker, ACE inhibitor, calcium antagonist, diuretic, acetyl 
salicylic acid, and statin) 
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Table 4 
 
Title: Cardiovascular mortality according to tertile of HDL cholesterol stratified for CAD in the ESTHER and AtheroGene cohorts 
 
             
 No CAD Stable CAD Unstable CAD 
 _____________________________ _____________________________ _____________________________ 
 N CD HR P N CD HR P N CD HR P 
             
AtheroGene 
Model 1 *             
1
st 
tertile 35 6 (17.1) 1.0 reference  674 65 (9.6) 1.0 reference  509 46 (9.0) 1.0 reference  
2
nd
 tertile 45 2 (4.4) 0.29 (0.06-1.44) 0.128 643 39 (6.1) 0.65 (0.43-0.96) 0.031 421 36 (8.6) 0.95 (0.62-1.48) 0.828 
3
rd
 tertile 73 2 (2.7) 0.16 (0.03-0.82) 0.027 673 42 (6.2) 0.57 (0.38-0.86) 0.007 340 26 (7.6) 0.68 (0.42-1.12) 0.127 
             
Model 2 †             
1
st 
tertile n.a. ‡ n.a. ‡ n.a. ‡ n.a. ‡ 663 65 (9.8) 1.0 reference  503 45 (8.9) 1.0 reference  
2
nd
 tertile     633 38 (6.0) 0.88 (0.58-1.33) 0.539 416 36 (8.7) 1.06 (0.67-1.69) 0.792 
3
rd
 tertile     659 41 (6.2) 0.73 (0.47-1.13) 0.159 337 26 (7.7) 0.90 (0.53-1.52) 0.685 
             
ESTHER 
Model 1 *             
1st tertile 1546 47 (3.0) 1.0 reference  362 37 (10.2) 1.0 reference  n.a. § n.a. § n.a. § n.a. § 
2nd tertile 1665 29 (1.7) 0.58 (0.36-0.92) 0.020 255 29 (11.4) 1.18 (0.72-1.93) 0.502     
3rd tertile 1728 35 (2.0) 0.74 (0.46-1.17) 0.199 182 19 (10.4) 1.14 (0.64-2.02) 0.659     
             
Model 2 †             
1st tertile 1184 37 (3.1) 1.0 reference  282 26 (9.2) 1.0 reference      
2nd tertile 1324 23 (1.7) 0.58 (0.34-1.00) 0.050 211 24 (11.4) 1.80 (0.98-3.33) 0.059     
3rd tertile 1410 29 (2.1) 0.80 (0.50-1.27) 0.226 151 14 (9.3) 1.70 (0.80-3.61) 0.168     
             
 
Legend: N number; CD number of cardiovascular deaths (percentage of tertile); HR hazard ratio; * adjusted for sex and age; † adjusted for sex, age, 
body mass index, systolic and diastolic blood pressure (hypertension in the AtheroGene cohort), diabetes, smoking, glomerular filtration rate, 
 24 
triglycerides, LDL cholesterol, and medication use (insulin, oral antidiabetic, ß-Blocker, ACE inhibitor, calcium antagonist, diuretic, acetyl salicylic 
acid, and statin); ‡ sample size too low; § no patients with unstable CAD in this cohort 
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Table 5 
 
Title: Results of meta-analyses for cardiovascular mortality according to tertile of HDL cholesterol stratified for coronary artery disease in the 
LURIC, ESTHER and AtheroGene cohorts 
 
    
 No CAD Stable CAD Unstable CAD 
 ________________________________ __________________________________ __________________________________ 
 HR P  Heterogeneity  
(Q; P; I²) 
HR P  Heterogeneity  
(Q; P; I²) 
HR P  Heterogeneity  
(Q; P; I²) 
          
Model 1 *          
1
st 
tertile 1.0 reference   1.0 reference   1.0 reference   
2
nd
 tertile 0.51 (0.35-0.73) <0.001 1.0; 0.61; 0% 0.77 (0.64-0.94) 0.009 3.7; 0.16; 45% 0.82 (0.63-1.07) 0.143 0.7; 0.40; 0% 
3
rd
 tertile 0.49 (0.34-0.71) <0.001 8.1; 0.02; 75% 0.67 (0.56-0.85) <0.001 3.8; 0.14; 48% 0.66 (0.49-0.90) 0.008 0.2; 0.88; 0% 
          
Model 2†‡           
1
st 
tertile 1.0 reference   1.0 reference   1.0 reference   
2
nd
 tertile 0.56 (0.37-0.86) 0.007 0.0; 0.87; 0% 0.92 (0.75-1.13) 0.440 5.3; 0.07; 62% 0.94 (0.71-1.25) 0.681 0.4; 0.53; 0% 
3
rd
 tertile 0.63 (0.43-0.94) 0.021 3.2; 0.07; 68% 0.84 (0.67-1.06) 0.148 3.8; 0.15; 48% 0.91 (0.65-1.27) 0.564 0.0; 0.98; 0% 
          
 
Legend: HR hazard ratio; * adjusted for sex and age; † adjusted for sex, age, body mass index, systolic and diastolic blood pressure, diabetes, 
smoking, glomerular filtration rate, triglycerides, LDL cholesterol, and medication use (insulin, oral antidiabetic, ß-Blocker, ACE inhibitor, calcium 
antagonist, diuretic, acetyl salicylic acid, and statin); for participants without CAD including data from LURIC and AtheroGene cohorts only 
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Supplementary text 1 
LURIC 2 
Clinical characterisation 3 
Information on socio-demographic characteristics, lifestyle and a history of common diseases 4 
were obtained by a comprehensive questionnaire from the study participants and from 5 
medical records at baseline (1). 6 
Diabetes mellitus was newly diagnosed according to the 2010 criteria of the American 7 
Diabetes Association. Thus, participants were categorised as diabetic if fasting plasma 8 
glucose was ≥126 mg/dl and/or plasma post-challenge glucose (plasma glucose 2 hours after 9 
the 75g glucose load) was ≥200 mg/dl and/or glycated hemoglobin was ≥6.5% (2). Moreover 10 
patients with a history of diabetes and those using oral anti-diabetics or insulin were 11 
considered diabetic. 12 
Hypertension was diagnosed if the systolic and/or diastolic blood pressure exceeded 140 13 
and/or 90 mmHg or if there was a history of hypertension, evident through the use of 14 
antihypertensive drugs (1). 15 
Cerebrovascular disease was defined clinically by documented history of a previous 16 
cerebrovascular disease event (transient ischaemic attack, prolonged ischaemic neurological 17 
deficit, cerebral infarction with or without a remaining neurological deficit) or by documented 18 
carotid plaques (≥50 % luminal obstruction) (1). 19 
Peripheral vascular disease was defined by a history of intermittent claudication, 20 
angiographic documentation of atherosclerotic luminal obstruction of the peripheral arteries 21 
or a history of a peripheral arterial intervention for atherosclerotic disease (angioplasty or 22 
surgery) (1). 23 
 24 
 25 
2 
 
Laboratory examination 1 
Creatinine was measured with the Jaffé method on a Hitachi 717 analyzer (1). The estimated 2 
glomerular filtration
 
rate was calculated as previously described (3). 3 
 4 
Statistical analysis 5 
Analyses on HDL functionality:  ANalysis Of VAriance models adjusted for the HDL 6 
cholesterol tertiles, sex, age, CAD, and the interaction term between the HDL cholesterol 7 
tertiles and CAD were performed to test whether the distributions of the apolipoproteins A1 8 
and A2 across the tertiles of HDL cholesterol differ among the different CAD categories.  9 
Analyses on cardiovascular mortality with adjustment for potential confounders: Interaction 10 
terms between the HDL cholesterol tertiles and medication use and clinical and biochemical 11 
characteristics were included in Cox model 2 to test whether the interaction between the HDL 12 
cholesterol tertiles and CAD independently predicts cardiovascular mortality.  13 
 14 
Results 15 
Analyses on HDL functionality: The interaction term between the HDL cholesterol tertiles and 16 
CAD was not associated with the apolipoproteins A1 (p=0.900) and A2 (p=0.987). 17 
Analyses on cardiovascular mortality with adjustment for potential confounders: The 18 
association of the interaction term between the HDL cholesterol tertiles and CAD with 19 
cardiovascular mortality remained significant (p=0.196 and p=0.023 for 2
nd
 and 3
rd
 tertile 20 
versus 1
st
 tertile, respectively) after inclusion of the interaction term between the HDL 21 
cholesterol tertiles and statin use in model 2. Significance for the interaction term between the 22 
HDL cholesterol tertiles and CAD with regard to cardiovascular mortality was also observed 23 
after inclusion of the interaction terms between the HDL cholesterol tertiles and use of acetyl 24 
salicylic acid (p=0.256 and p=0.017 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), ß-25 
blockers (p=0.246 and p=0.007 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), ACE 26 
3 
 
inhibitors (p=0.150 and p=0.005 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), calcium 1 
antagonists (p=0.169 and p=0.006 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), 2 
diuretics (p=0.201 and p=0.008 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), oral 3 
antidiabetics (p=0.171 and p=0.007 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), and 4 
insulin (p=0.162 and p=0.005 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively). The 5 
interaction between the HDL cholesterol tertiles and CAD also remained a significant 6 
predictor of cardiovascular mortality after adjustment for the interaction between the HDL 7 
cholesterol tertiles and gender (p=0.212 and p=0.010 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, 8 
respectively), age (p=0.221 and p=0.017 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), 9 
body mass index (p=0.218 and p=0.007 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), 10 
diabetes mellitus (p=0.169 and p=0.005 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, respectively), 11 
systolic blood pressure (p=0.196 and p=0.012 for 2
nd
 and 3
rd
 tertile versus 1
st
 tertile, 12 
respectively), diastolic blood pressure (p=0.165 and p=0.010 for 2
nd
 and 3
rd
 tertile versus 1
st
 13 
tertile, respectively), glomerular filtration rate (p=0.174 and p=0.010 for 2
nd
 and 3
rd
 tertile 14 
versus 1
st
 tertile, respectively), LDL cholesterol (p=0.194 and p=0.010 for 2
nd
 and 3
rd
 tertile 15 
versus 1
st
 tertile, respectively), triglycerides (p=0.194 and p=0.010 for 2
nd
 and 3
rd
 tertile 16 
versus 1
st
 tertile, respectively), and smoking (p=0.172 and p=0.006 for 2
nd
 and 3
rd
 tertile 17 
versus 1
st
 tertile, respectively). 18 
 19 
AtheroGene 20 
Clinical characterisation 21 
Information on socio-demographic characteristics, lifestyle and a history of common diseases 22 
were obtained by a comprehensive questionnaire from the study participants and from 23 
medical records at baseline (4). 24 
4 
 
Diabetes mellitus was diagnosed if fasting plasma glucose was ≥126 mg/dl. Moreover, 1 
patients with a history of diabetes and those using oral anti-diabetics or insulin were 2 
considered diabetic (4). 3 
Hypertension was diagnosed if there was a history of hypertension or ongoing use of 4 
antihypertensive drugs (4)  5 
 6 
Laboratory examination 7 
Creatinine was measured with was measured by the modified Jaffe routine method (5). 8 
Estimated glomerular filtration rate was calculated according to the Cockroft–Gault (6)  9 
 10 
ESTHER 11 
Clinical characterisation 12 
Information on socio-demographic characteristics, lifestyle and a history of common diseases 13 
were obtained by a comprehensive questionnaire from the study participants at baseline.  14 
Diabetes mellitus was diagnosed based on reports of physicians.  In addition, diabetes was 15 
identified by use of anti-diabetic medication and/or fasting plasma glucose ≥126 mg/dl and/or 16 
non-fasting glucose ≥200 mg/dl and/or glycated hemoglobin ≥6.5% (7). 17 
Hypertension was diagnosed based on reports of physicians. In addition, hypertension was 18 
identified by use of antihypertensive drugs and/or self-reported hypertension plus a systolic 19 
blood pressure ≥140 and/or a diastolic blood pressure ≥90 mmHg. 20 
Cerebrovascular disease was self-reported by study participants in the standardized 21 
questionnaire in a question on any kind of stroke in the past.  22 
Peripheral vascular disease was defined by a self-reported history of a balloon dilatation of 23 
the of leg arteries. 24 
 25 
 26 
5 
 
Laboratory examination 1 
Serum creatinine was determined by kinetic Jaffé method (8). Estimated glomerular filtration 2 
rate was calculated according to the Modification of Diet in Renal Disease equation (9) 3 
6 
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Supplementary table 1 
 
 
Title: Baseline characteristics according to tertile of HDL cholesterol in LURIC stratified for CAD 
 
             
 No CAD Stable CAD Unstable CAD 
 _______________________________ _______________________________ ________________________________ 
 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 
             
Number 142 233 324  509 535 471  397 315 215  
Male sex 37 (26.1) 109 (46.8) 190 (58.6) <0.001 432 (84.9) 419 (78.3) 294 (62.4) <0.001 331 (83.4) 233 (74.0) 119 (55.3) <0.001 
Age, years 55.6±13.0 58.0±11.3 59.7±11.5 0.002 63.1±10.3 63.8±9.1 65.2±9.1 0.002 62.5 ±10.8 63.7 ± 10.1 65.7 ± 9.6 0.001 
Body mass index, kg/m² 28.2±4.3 28.0±4.6 26.7±4.0 <0.001 28.1±4.1 27.8±4.0 26.5±3.7 <0.001 28.0 ± 4.2 27.8 ± 3.7 26.6 ± 4.0 <0.001 
Waist circumference, cm † 100±12 98±12 94±12 <0.001 101±11 100±12 97±12 <0.001 102 ± 12 101 ± 10 97 ± 12 <0.001 
Hypertension 89 (62.7) 148 (63.5) 206 (63.6) 0.981 392 (77.0) 415 (77.6) 363 (77.1) 0.973 286 (72.0) 235 (74.6) 163 (75.8) 0.551 
Systolic blood pressure, mmHg 132±22 138±22 137±23 0.029 143±23 146±23 147±23 0.005 137±25 140±22 141±21 0.140 
Diastolic blood pressure, mmHg 78±12 81±11 81±11 0.030 81±11 83±11 83±11 0.006 79±12 80±11 81±11 0.139 
Diabetes mellitus 56 (39.4) 69 (29.6) 62 (19.1) <0.001 260 (51.1) 223 (41.7) 165 (35.0) <0.001 194 (48.9) 146 (46.3) 66 (30.7) <0.001 
Smoking    0.001    <0.001    <0.001 
Never 55 (38.7) 119 (51.1) 186 (57.4)  129 (25.3) 164 (30.7) 196 (41.6)  101 (25.4) 100 (31.7) 86 (40.0)  
Former smoker 53 (37.3) 63 (27.0) 96 (29.6)  278 (54.6) 286 (53.5) 220 (46.7)  173 (43.6) 143 (45.4) 94 (43.7)  
Current smoker 34 (23.9) 51 (21.9) 42 (12.0)  102 (20.0) 85 (15.9) 55 (11.7)  123 (31.0) 72 (22.9) 35 (16.3)  
Lipids‡             
Total cholesterol, mg/dl 183±43 197±35 207±32 <0.001 182±40 197±37 203±38 <0.001 180 ± 40 187 ± 37 198 ± 35 <0.001 
LDL cholesterol, mg/dl  103±31 122±31 126±29 <0.001 106±36 121±32 124±35 <0.001 108 ± 35 116 ± 32 122 ± 32 <0.001 
HDL cholesterol, mg/dl  29±4 38±3 53±9 <0.001 28±4 38±3 51±7 <0.001 28 ± 4 37 ± 2 51 ± 8 <0.001 
VLDL cholesterol, mg/dl 50±44 37±22 28±19 <0.001 47±32 38±26 29±18 <0.001 44 ± 29 34 ± 20 51 ± 8 <0.001 
Triglycerides, mg/dl  172 (120-267) 147 (109-208) 115 (88-156) <0.001 173 (127-242) 148 (112-201) 122 (94-164) <0.001 172  (133-230) 153 (118-196) 129 (98-162) <0.001 
Apolipoprotein A1, mg/dl 109±17 130±13 158±21 <0.001 109±15 129±13 155±18 <0.001 105±14 125±13 152±18 <0.001 
Apolipoprotein A2, mg/dl 36±8 42±7 49±10 <0.001 36±8 42±8 48±9 <0.001 35±8 41±7 46±8 <0.001 
Apolipotrotein B, mg/dl 103±24 106±23 100±21 0.007 106±26 107±24 103±25 0.017 108±28 104±24 100±23 0.001 
GFR, ml/min/1.73m² 83±20 84±17 82±17 0.587 80±20 83±18 82±18 0.063 79±21 81±20 79±18 0.540 
Presentation of unstable CAD            <0.001 
Unstable angina 0 0 0 n.a. 0 0 0 n.a. 223 (56.2) 217 (68.9) 181 (84.2)  
NSTEMI 0 0 0  0 0 0  61 (15.4) 34 (10.8) 19 (8.8)  
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STEMI 0 0 0  0 0 0  113 (28.5) 64 (20.3) 15 (7.0)  
NYHA functional class    0.424    0.152    0.044 
1 65 (45.8) 108 (46.4) 163 (50.3)  236 (46.4) 287 (53.6) 235 (49.9)  226 (56.9) 174 (55.2) 111 (51.6)  
2 47 (33.1) 82 (35.2) 109 (33.6)  159 (31.2) 160 (29.9) 153 (32.5)  96 (24.2) 77 (24.4) 52 (24.2)  
3 28 (19.7) 38 (16.3) 41 (12.7)  98 (19.3) 79 (14.6) 73 (15.5)  63 (15.9) 40 (12.7) 43 (20.0)  
4 2 (1.4) 5 (2.1) 11 (3.4)  16 (3.1) 9 (1.7) 10 (2.1)  12 (9.0) 24 (7.6) 9 (4.2)  
Left ventricular function (echo) ||    <0.001    <0.001    <0.001 
Normal 87 (62.1) 160 (70.8) 255 (80.2)  269 (55.5) 326 (62.7) 322 (69.7)  186 (47.1) 179 (57.6) 146 (68.2)  
Mildly impaired 12 (8.6) 24 (10.6) 32 (10.1)  89 (18.4) 82 (15.8) 62 (13.4)  62 (15.7) 49 (15.8) 22 (10.3)  
Moderately impaired 18 (12.9) 26 (11.5) 16 (5.0)  75 (15.5) 68 (13.1) 48 (10.4)  43 (10.9) 29 (9.3) 12 (5.6)  
Severely impaired 18 (12.9) 9 (4.0) 7 (2.2)  37 (7.6) 18 (3.5) 14 (3.0)  22 (5.6) 9 (2.9) 7 (3.3)  
Peripheral vascular disease 4 (2.8) 5 (2.1) 6 (1.9) 0.803 83 (16.3) 59 (11.0) 42 (8.9) 0.001 60 (15.1) 22 (7.0) 18 (8.4) 0.001 
Cerebrovascular disease 9 (6.3) 17 (7.3) 15 (4.6) 0.403 75 (14.7) 41 (7.7) 34 (7.2) <0.001 39 (9.8) 29 (9.2) 27 (12.6) 0.428 
Medication use             
Insulin 2 (1.4) 4 (1.7) 1 (0.3) 0.222 38 (7.5) 38 (7.1) 25 (5.3) 0.353 30 (7.6) 17 (5.4) 12 (5.6) 0.435 
Oral antidiabetic 10 (7.0) 9 (3.9) 6 (1.9) 0.020 59 (11.6) 48 (9.0) 30 (6.4) 0.017 56 (14.1) 27 (8.6) 10 (4.7) 0.001 
ß-Blocker 64 (45.1) 116 (49.8) 131 (40.4) 0.090 348 (68.4) 334 (62.4) 266 (56.5) <0.001 318 (80.1) 247 (78.4) 155 (72.1) 0.070 
ACE inhibitor 60 (42.3) 90 (38.6) 101 (31.2) 0.041 298 (58.5) 276 (51.6) 234 (49.7) 0.013 279 (70.3) 199 (63.2) 120 (55.8) 0.001 
Calcium antagonist 15 (10.6) 34 (14.6) 45 (13.9) 0.514 91 (17.9) 94 (17.6) 92 (19.5) 0.694 50 (12.6) 41 (13.0) 37 (17.2) 0.253 
Diuretic 54 (38.0) 57 (24.5) 66 (20.4) <0.001 197 (38.7) 151 (28.2) 120 (25.5) <0.001 115 (29.0) 78 (24.8) 58 (27.0) 0.455 
Statin 34 (23.9) 41 (17.6) 52 (16.0) 0.122 267 (52.5) 284 (53.1) 232 (49.3) 0.438 274 (69.0) 205 (65.1) 124 (57.7) 0.019 
Acetyl salicylic acid 52 (36.6) 109 (46.8) 136 (42.0) 0.150 385 (75.6) 387 (72.3) 350 (74.3) 0.472 353 (88.9) 277 (87.9) 186 (86.5) 0.681 
             
 
Legend: Values are numbers (percentages) for categorical data and means ± standard deviations or medians (25
th
-75
th
 percentiles) for continuous 
variables; * for differences across the three groups calculated with chi-square test and ANalysis Of VAriance for categorical and continuous data, 
respectively; † number: 140/232/321/501/528/463/394/313/210; ‡ to convert values for total, LDL, HDL, and VLDL cholesterol to millimoles per 
liter, multiply by 0.02586; to convert values for triglycerides to millimoles per liter, multiply by 0.01129; § ANalysis Of VAriance of 
logarithmically transformed values; || number 140/226/318/485/520/462/395/311/214 
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Supplementary table 2 
 
Title: Baseline characteristics according to tertile of HDL cholesterol in AtheroGene stratified for CAD 
 
             
 No CAD Stable CAD Unstable CAD 
 _______________________________ _______________________________ ________________________________ 
 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 
             
Number 35   45  73  674 643 673  509 421 340  
Male sex 16 (45.7) 28 (62.2) 31 (42.5) 0.100 587 (87.1) 537 (83.5) 417 (62) <0.001 421 (82.7) 327 (77.7) 204 (60) <0.001 
Age, years 59.0±10.5 57.9±9.3 62.8±9.4 0.017 61.3±10 61.7±9.7 63.7±9 <0.001 60.2±10.9 60.6±10.5 64.1±9.8 <0.001 
Body mass index, kg/m² 28.3±4.4 27.5±3.7 26.1±3.7 0.015 28.4±3.9 27.6±4.1 26.6±3.8 <0.001 28.1±4 27.2±3.7 26.5±3.7 <0.001 
Waist circumference, cm  n.a. n.a. n.a.  n.a. n.a. n.a.  n.a. n.a. n.a.  
Hypertension 20 (57.1) 25 (55.6) 46 (63.0) 0.69 535 (79.4) 502 (78.1) 537 (79.8) 0.73 370 (72.7) 271 (64.4) 230 (67.6) 0.022 
Diabetes mellitus 9 (25.7) 4 (8.9) 6 (8.2) 0.025 205 (30.4) 130 (20.2) 123 (18.3) <0.001 125  (24.6) 71 (16.9) 62 (18.2) 0.008 
Smoking    0.583    <0.001    <0.001 
Never 20 (57.1) 22 (48.9) 47 (64.4)  222 (32.9) 230 (35.8) 286 (42.5)  154 (30.3) 150 (35.6) 157 (46.2)  
Former smoker 4 (11.4) 6 (13.3) 6 (8.2)  240 (35.6) 244 (37.9) 240 (35.7)  183 (36) 154 (36.6) 96 (28.2)  
Current smoker 11 (31.4) 17 (37.8) 20 (27.4)  212 (31.5) 169 (26.3) 147 (21.8)  171 (33.7) 117 (27.8) 87 (25.6)  
Lipids †             
Total cholesterol, mg/dl 220±34 224±38 230±45 0.50 189±46 203±47 219±46 <0.001 195±46 214±43 224±47 <0.001 
LDL cholesterol, mg/dl  140±30 146±33 136±39 0.29 119±40 129±42 132±44 <0.001 125±40 139±42 137±41 <0.001 
HDL cholesterol, mg/dl  35±5 48±3.4 70±14 <0.001 36±5 48±3 66±12 <0.001 36±6 48±3 65±12 <0.001 
Triglycerides, mg/dl  205 (160-273) 140 (98-196) 109 (77- 156) <0.001 165 (119-232) 134 (98- 185) 109 (82-145) <0.001 159 (115-224) 137 (102-189) 105 (80-141) <0.001 
GFR, ml/min/1.73m² 71±22 72±16 70±12 0.81 76±21 80±20 79±21 <0.001 79±22 82±25 78±21 0.094 
Presentation of unstable CAD            0.006 
Unstable angina 0 0 0  0 0 0  256 (50.3) 229 (54.4) 204 (60)  
NSTEMI 0 0 0  0 0 0  128 (50.6) 96 (50) 66 (48.5)  
STEMI 0 0 0  0 0 0  44 (17.4) 54 (28.1) 33 (24.3)  
MI (not classified) 0 0 0  0 0 0  81 (32) 42 (21.9) 37 (27.2)  
Medication use             
Insulin 3 (8.6) 1 (2.2) 3 (4.1) 0.39 80 (11.9) 45 (7) 46 (6.8) <0.001 40 (7.) 31 (7.4) 23 (6.8) 0.84 
Oral antidiabetic 5 (14.3) 2 (4.4) 0 (0.0) 0.004 89 (13.2) 51 (7.9) 54 (8) <0.001 53 (10.4) 27 (6.4) 21 (6.2) 0.030 
ß-Blocker 11 (31.4) 17 (37.8) 27 (37.0) 0.81 434 (64.6) 414 (64.4) 363 (53.9) <0.001 351 (69) 280 (66.7) 219 (64.4) 0.38 
ACE inhibitor 17 (48.6) 19 (42.2) 30 (41.1) 0.76 371 (55) 340 (52.9) 334 (49.6) 0.13 267 (52.5) 203 (48.3) 160 (47.1) 0.25 
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Calcium antagonist 5 (14.3) 7 (15.6) 11 (15.1) 0.99 130 (19.3) 105 (16.3) 116 (17.2) 0.35 58 (11.4) 39 (9.3) 40 (11.8) 0.47 
Diuretic 13 (37.1) 13 (28.9) 15 (20.5) 0.18 231 (34.3) 179 (27.8) 199 (29.6) 0.031 132 (25.9) 110 (26.2) 87 (25.6) 0.98 
Statin 6 (17.1) 12 (26.7) 17 (23.3) 0.60 341 (50.6) 325 (50.5) 357 (53) 0.58 184 (36.1) 143 (34) 138 (40.6) 0.17 
Acetyl salicylic acid 23 (65.7) 31 (68.9) 46 (63.0) 0.81 575 (85.6) 551 (85.7) 550 (81.7) 0.077 430 (84.5) 354 (84.3) 284 (83.5) 0.93 
             
  
Legend: Values are numbers (percentages) for categorical data and means ± standard deviations or medians (25
th
-75
th
 percentiles) for continuous 
variables; * for differences across the three groups calculated with chi-square test and ANalysis Of VAriance for categorical and continuous data, 
respectively; †  to convert values for total, LDL, HDL, and VLDL cholesterol to millimoles per liter, multiply by 0.02586; to convert values for 
triglycerides to millimoles per liter, multiply by 0.01129; ‡ ANalysis Of VAriance of logarithmically transformed values  
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Supplementary table 3 
 
Title: Baseline characteristics according to tertile of HDL cholesterol in ESTHER stratified for CAD 
 
         
 No CAD Stable CAD 
 _______________________________ _________________________________ 
 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 1
st
 tertile 2
nd
 tertile 3
rd
 tertile P* 
         
Number 1546 1665 1728  362 255 182  
Male sex 969 (62.7) 741 (44.5) 404 (23.4) <0.001 268 (74.1) 148 (58.0) 76 (41.8) <0.001 
Age, years 61.1±6.6 61.7±6.6 61.6±6.6 0.050 64.5±6.2 65.1±5.6 66.6±5.1 <0.001 
Body mass index, kg/m² 28.8±4.2 27.8±4.2 26.2±3.9 <0.001 29.0±4.5 28.1±4.5 27.5±4.8 <0.001 
Hypertension 891 (57.6) 850 (51.1) 743 (43.0) <0.001 334 (92.3) 223 (87.5) 147 (80.8) <0.001 
Systolic blood pressure, mmHg 141±19 140±20 138±20 <0.001 141±18 143±19 143±19 0.345 
Diastolic blood pressure, mmHg 85±11 84±10 83±11 <0.001 82±10 84±11 84±9 0.087 
Diabetes mellitus 302 (19.6) 208 (12.5) 117 (6.8) <0.001 138 (38.2) 72 (28.2) 36 (19.8) <0.001 
Smoking    <0.001    0.008 
Never 637 (42.1) 863 (52.9) 1025 (60.7)  126 (36.2) 116 (46.6) 92 (52.0)  
Former smoker 557 (36.8) 524 (32.1) 454 (26.9)  163 (46.8) 99 (39.8) 65 (36.7)  
Current smoker 318 (21.0) 244 (15.0) 209 (12.4)  59 (17.0) 34 (13.7) 20 (11.3)  
Lipids‡         
Total cholesterol, mg/dl 214±52 224±48 234±50 <0.001 200±54 217±51 218±47 <0.001 
LDL cholesterol, mg/dl  148±38 151±35 148±36 0.024 137±40 145±42 142±36 0.040 
HDL cholesterol, mg/dl  38±6 52±4 71±11 <0.001 37±6 52±4 69±9 <0.001 
Triglycerides, mg/dl  149 (107-220) 115 (81-157) 89 (66-121) <0.001 142 (101-211) 115 (84-164) 87 (68-115) <0.001 
GFR, ml/min/1.73m² 90±40 87±33 87±34 0.019 88±39 83±30 84±34 0.176 
Peripheral vascular disease 12 (0.8) 18 (1.1) 20 (1.2) 0.521 17 (4.8) 11 (4.4) 4 (2.2) 0.344 
Cerebrovascular disease 57 (3.8) 37 (2.3) 27 (1.6) <0.001 31 (9.0) 15 (6.2) 16 (9.2) 0.402 
Medication use         
Insulin 47 (3.0) 21 (1.3) 17 (1.0) <0.001 24 (6.6) 14 (5.5) 6 (3.3) 0.275 
Oral antidiabetic 134 (8.7) 68 (4.1) 29 (1.7) <0.001 54 (14.9) 22 (8.6) 13 (7.1) 0.008 
ß-Blocker 341 (22.1) 321 (19.3) 248 (14.4) <0.001 170 (50.0) 119 (46.7) 60 (33.0) 0.004 
ACE inhibitor 351  (22.7) 298 (17.9) 247 (14.3) <0.001 167 (46.1) 101 (39.6) 77 (42.3) 0.263 
Calcium antagonist 163 (10.5) 140 (8.4) 140 (8.1) 0.031 107 (29.6) 65 (25.5) 57 (31.3) 0.363 
Diuretic 110 (7.1) 112 (6.7) 87 (5.0) 0.031 86 (23.8) 54 (21.2) 38 (20.9) 0.657 
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Statin 158 (10.2) 132 (7.9) 157 (9.1) 0.077 136 (37.6) 96 (37.7) 45 (24.7) 0.006 
Acetyl salicylic acid 119 (7.7) 114 (6.9) 94 (5.4) 0.031 161 (44.5) 97 (38.0) 59 (32.4) 0.021 
         
 
Legend: Values are numbers (percentages) for categorical data and means ± standard deviations or medians (25
th
-75
th
 percentiles) for continuous 
variables; * for differences across the three groups calculated with chi-square test and ANalysis Of VAriance for categorical and continuous data, 
respectively; ‡ to convert values for total, LDL, HDL, and VLDL cholesterol to millimoles per liter, multiply by 0.02586; to convert values for 
triglycerides to millimoles per liter, multiply by 0.01129; § ANalysis Of VAriance of logarithmically transformed values  
 
